[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myeloma-multiple\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myeloma-multiple":580},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,49,81,106,139,168,190,209,225,265,285,310,331,358,380,418,443,469,506,534,558],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644725","immune-fitness-in-older-patients-with-relapsed-and-refractory-multiple-myeloma-100644725",false,"NCT07674498","Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma","Prediction of Response Related to IMmune Age T Cell Fitness in Elderly Patients With Relapsed and Refractory Multiple Myeloma","PRIME","Inclusion Criteria:\n\n* ≥ 65 years old\n* Relapsed\u002Frefractory multiple myeloma\n* Eligible for a CAR-T cell or bispecific antibody therapies\n\nExclusion Criteria:\n\n* \\\u003C65 years old\n* Active cancer other than myeloma\n* Active AL amyloidosis\n* Central nervous system (CNS) involvement","ALL","65 Years",{"count":20,"type":21},31,"ESTIMATED","INTERVENTIONAL",[24],"NA","Relapsed\u002Frefractory multiple myeloma (RRMM) predominantly affects older adults, who exhibit marked heterogeneity in treatment outcomes despite receiving the same therapies. Clinical frailty scores, such as the International Myeloma Working Group (IMWG) Frailty Index, predict survival and treatment tolerance but provide limited information on immune competence, a key determinant of response to T-cell-based immunotherapies.\n\nThe PRIME study is a prospective, multicenter, non-interventional exploratory study designed to evaluate the relationship between immune fitness and clinical outcomes in patients aged 65 years or older with RRMM treated with standard-of-care chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies. Peripheral blood samples collected before treatment initiation will be analyzed to characterize T-cell differentiation, activation, senescence, exhaustion, and T-helper cell subsets using multiparametric immunophenotyping. Serum biomarkers, including soluble B-cell maturation antigen (sBCMA) and senescence-associated soluble markers, will also be assessed.\n\n* The primary objective is to determine whether baseline immune profiles are associated with quality of response at 3 months after treatment initiation.\n* Secondary objectives include evaluating the association between immune profiles and treatment-related toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), other neurological toxicities, and infectious complications. Exploratory analyses will integrate immune, geriatric, sarcopenia, and clinical variables using statistical approaches to identify novel predictors of efficacy, survival, and toxicity.\n\nBy combining immune phenotyping with frailty assessment, the PRIME study aims to improve biological risk stratification and support the development of more personalized treatment strategies for older patients with multiple myeloma.",[27],"Myeloma Multiple",[29,30,31,32,33,34,35],"multiple myeloma","immunosenescence","Exhaustion","T-fitness","T lymphocyte","elderly","T cell therapies","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2026-06-03",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"Jules Bordet Institute","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100642240","phase-1-a-multicenter-study-of-belantamab-mafodotin-and-mezigdomide-in-patients-with-relapsed-multiple-myeloma-100642240","NCT07612787","A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma","A Multicenter Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Combination With a Phase Ib Safety Run in Patients With Relapsed Multiple Myeloma Following BCMA-targeting CAR-T Cells or Bispecific Antibodies","BELAMI","Inclusion Criteria:\n\n* Subjects who are ≥ 18 years of age\n* Participant has a histologically or cytologically confirmed diagnosis of MM as defined by IMWG criteria\n* Participant has Eastern Cooperative Oncology Group (ECOG) performance status of score of 0, 1, or 2\n* Participant is considered transplant ineligible or for participants with a history of autologous stem cell transplant (ASCT), ASCT was \\>100 days before initiating study treatment\n* Participant has measurable disease with at least one of the following criteria:\n\n  * Serum M protein \\>0.5 g\u002FdL (\\>5 g\u002FL), or\n  * Urine M protein \\>200 mg\u002F24h, or\n  * Serum free light chain (FLC) assay: Involved FLC level \\>5 mg\u002FdL (\\>50 mg\u002FL) and an abnormal serum FLC ratio (\\\u003C0.26 or \\>1.65)\n* Participant is quadruple-class exposed or refractory (anti-CD38 antibody (e.g., daratumumab, isatuximab) alone or in combination, immunomodulatory agent (e.g., lenalidomide, pomalidomide), a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib) and BCMA-directed CAR-T cells and\u002For anti-BCMA bispecific antibodies) and has failed at least 3 prior lines of anti-myeloma therapies\n* Documented presence of BCMA.\n* All prior treatment related toxicities (defined by NCI-CTCAE Version 5.0) must be Grade ≤1 at the time of enrollment, except for alopecia and Grade 2 hematological, hepatic and renal laboratory values.\n* Participant must have adequate organ function at minimum, defined in Table 2 \"adequate organ function\".\n* Life expectancy of at least 6 months, in the opinion of the investigator\n* Sex and Contraceptive\u002FBarrier Requirements\n* Participants must adhere to contraceptive guidelines on contraception methods in clinical studies to minimize the risk of pregnancy\n* Signed informed consent\n* Participant affiliated to or a beneficiary of a social security category\n\nExclusion Criteria:\n\n* Patients under guardianship or curators\n* Patients with insufficient proficiency in French to understand the study information\n* Prior treatment with an anti-BCMA targeted therapy within 90 days of receiving the first dose of study drugs, or treatment with an investigational agent or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or 5 half-lives of receiving the first dose of study drugs.\n* A known intolerance or immediate or delayed hypersensitivity to drugs chemically related to Belantamab mafodontin or Mezigdomide or any of of the components of the study treatment.\n* Prior treatment with an antibody-drug conjugate.\n* Prior treatment with Mezigdomide.\n* Prior allogeneic stem cell transplant.\n* Any major surgery within 4 weeks before the first dose of study drug (or 2 weeks if clinically stable). Additional exception allowed for bone-stabilizing surgery after consultation with medical monitor.\n* Has received a live or attenuated vaccine within 30 days before the first dose of study treatment.\n* Participant has received plasmapheresis ≤ 7 days before the first dose of study treatment.\n* Presence of active renal condition (infection, requirement for dialysis, or any other condition that could affect participant's safety).\n* Any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with the study procedures.\n* Evidence of active mucosal or internal bleeding.\n* Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.\n* Evidence of cardiovascular risk.\n* Participant has malignancies other than MM are excluded, except for any other malignancy from which the participant has been disease free for \\>5 years with the exception of the following noninvasive malignancies: basal or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer (T1a or T1b using the tumor, nodes, and metastases clinical staging system), or prostate cancer that is curative.\n* Active infection requiring antibiotic, antiviral, or antifungal therapy.\n* Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, skin changes) or active plasma cell leukemia at the time of screening.\n* Current corneal epithelial disease, except mild punctuate keratopathy.\n* Contact lenses are not allowed for participants while they are receiving Belantamab mafodontin treatment. Contact lens use may be restarted after discontinuation of Belantamab mafondontin treatment, provided the eye-care specialist confirms there are no other contraindications.\n* Treatment with strong CYP3A4\u002F5 modulators or Potassium-Competitive Acid Blockers or Proton Pump Inhibitors or unable to absorb oral therapies (i.e. gastric surgery).\n* Participant is a pregnant or lactating female.\n* Participant with known HIV infection is excluded, unless the specific criteria (see relative section) are met.\n* Patient with a presence of hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb) at screening or within 3 months before first dose of study treatment should be excluded, unless the criteria described in the relative section are met.\n* Participant with a positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before first dose of study treatment are excluded, unless the criteria described in the relative section are met.","18 Years",{"count":59,"type":21},44,[61,62],"PHASE1","PHASE2","The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in.\n\nThe primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD will be efficient for these patients.",[27],[66,67,68,69],"cancer","hematology","relapse","antibody","NOT_YET_RECRUITING","2026-06-11",{"date":73,"type":40},"2026-06-15",{"date":75,"type":21},"2026-06-01",{"date":77,"type":21},"2031-01-01",{"name":79,"class":47},"Centre Hospitalier Universitaire de Saint Etienne",30,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100559046","determine-the-frequency-of-variants-in-the-gbapsap-genes-in-patients-with-mm-or-mgus-100559046","NCT06559033","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With MM or MGUS","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)","GAMY","Inclusion Criteria:\n\n* Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g\u002FL and no clinical involvement).\n* Membership of a social security scheme\n* Adult having read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub-guardianship or guardianship",true,{"count":91,"type":21},300,"OBSERVATIONAL","No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.",[95,27],"Monoclonal Gammopathy of Undetermined Significance","2026-06-08",{"date":98,"type":40},"2026-06-10",{"date":100,"type":40},"2025-10-07",{"date":102,"type":21},"2027-04-01",{"name":104,"class":47},"University Hospital, Rouen",2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100489347","phase-1-a-study-of-an-mmset-inhibitor-in-patients-with-relapsed-and-refractory-multiple-myeloma-100489347","NCT05651932","A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma","Key Inclusion Criteria for Dose-Expansion:\n\n* ≥ 18 years of age\n* ECOG score ≤ 1\n* Multiple myeloma (as per IMWG)\n\n  * Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antibody. For mezigdomide combination Cohorts B1 and B2, participants must have received at least 2 prior lines of therapy\n  * Participants must have a confirmed diagnosis of progressive MM (per IMWG), t(4;14) confirmed by fluorescence in situ hybridization (FISH) testing performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory via fresh tumor biopsy.\n* Measurable disease, including at least 1 of the following criteria:\n\n  * Serum M protein ≥ 0.50 g\u002FdL (by SPEP)\n  * Serum IgA ≥ 0.50 g\u002FdL (IgA myeloma patients)\n  * Urine M protein ≥ 200 mg\u002F24 h (by UPEP)\n  * sFLC involved light chain ≥ 10 mg\u002FdL (100 mg\u002FL) (patients with abnormal sFLC ratio)\n  * Bone marrow plasma cells ≥ 30% (if only criterion for measurability)\n* Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)\n\nKey Exclusion Criteria for Dose-Expansion:\n\n* Treatment with the following therapies in the specified time period prior to first dose:\n\n  * Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment\n  * Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2\n  * Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D\n  * Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks\n  * Cellular therapies ≤ 8 weeks\n  * Autologous transplant \\\u003C 100 days\n  * Allogenic transplant ≤ 6 months, or \\> 6 months with active GVHD\n  * Major surgery ≤ 4 weeks\n* Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis\n* Active CNS disease: participants with previously treated stable CNS disease are eligible, except for Cohorts B1 and B2 for which known CNS myeloma involvement is completely excluded.\n* Inadequate bone marrow function\n* Inadequate renal, hepatic, pulmonary, and cardiac function\n* Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.\n* Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 7 days or 5 half-lives (whichever is longer) prior to first dose\n* Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)\n* Active malignancy not related to myeloma requiring therapy within \\\u003C 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.",{"count":114,"type":21},165,[61],"A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2\u002FWHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).",[118,119,27],"Multiple Myeloma","Myeloma",[121,122,123,124,125,126,127,128],"NSD2","MMSET","WHSC1","T4;14","T(4;14)","translocation","myeloma","RRMM","2026-06-04",{"date":96,"type":40},{"date":132,"type":40},"2023-02-22",{"date":134,"type":21},"2028-06-30",{"name":136,"class":137},"K36 Therapeutics, Inc.","INDUSTRY",22,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":92,"phases":4,"briefSummary":149,"conditions":150,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":105},"100640045","infectious-complications-in-hematological-patients-under-treatment-with-bispecific-antibodies-100640045","NCT07609576","Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.","Multicenter Study Proposal: Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.","Inclusion Criteria:\n\n1. Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies.\n2. Patients must have initiated BsAb therapy within 30 days prior to study enrollment.\n3. Ability to provide informed consent.\n4. Severe infections will be recorded the first year, but infectious events past confirmed relapse or new treatments for the underlying disease will not be recorded.",{"count":147,"type":21},350,"2 Months","This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.\n\nSecondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.",[151,27,152,153,154,155],"Lymphoma Neoplasms","Severe Infection","CMV Reactivation","Biespecific Treatment","Biespecific",[157,158],"prophylaxis","infections management","2026-05-21",{"date":161,"type":40},"2026-05-27",{"date":163,"type":40},"2026-05-14",{"date":165,"type":21},"2026-06-30",{"name":167,"class":47},"Infanta Leonor University Hospital",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100639133","phase-1-etenta-isa-vrd-in-newly-diagnosed-high-risk-multiple-myeloma-100639133","NCT07600151","Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma","A Clinical Phase I\u002FII, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients","CONQUISTADOR","Inclusion Criteria:\n\n* Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria.\n* Participants must have High-risk myeloma according to IMS\u002FIMWG CGS\n* Participants must be considered a candidate for high-dose chemotherapy and ASCT, as described in the protocol.\n* Participants must have measurable disease as defined in the protocol. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions).\n* Participants must have clinical laboratory values within a prespecified range.\n\nExclusion Criteria:\n\n* Known contraindications to the use of any IMP or axMP or required concomitant drugs or supportive treatment.\n* known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia\n* Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma first-line treatment within the specifications of the protocol\n* known central nervous system involvement by MM.",{"count":177,"type":21},220,[61,62],"This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.",[27,119],{"date":182,"type":40},"2026-05-20",{"date":184,"type":21},"2026-12-01",{"date":186,"type":21},"2036-12-31",{"name":188,"class":47},"Universitätsklinikum Hamburg-Eppendorf",1,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":189},"100639230","mmappin-study-multiple-myeloma-analysis-for-patient-specific-insights-to-dissect-disease-heterogeneity-100639230","NCT07582354","MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity","Inclusion Criteria:\n\n* Age 18+\n* Signed CI for study partecipation and personal data processing.\n* Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM\u002FRMM\u002FRRMM)\n\nExclusion Criteria:\n\n* None",{"count":197,"type":21},520,"This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.\n\nThe study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.",[27],"2026-05-07",{"date":202,"type":40},"2026-05-12",{"date":204,"type":40},"2025-10-15",{"date":206,"type":21},"2032-09-29",{"name":208,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":189},"100614717","anonymization-of-clinical-data-from-pseudonymized-databases-collected-as-part-of-previus-clinical-trials-on-multiple-myeloma-100614717","NCT07283224","Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥18 years\n* Signed Informed Consent\n* Patients with confirmed diagnosis of MM, previously enrolled in spontaneous trial conducted at the UOC Ematologia, IRCCS AOU di Bologna, from 2021, for whom pseudonymized datasets are already available at the start of this study.\n\nExclusion Criteria:\n\n* None",{"count":216,"type":21},600,"This is a retrospective, observational, single-center study conducted at the Hematology Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The study aims to integrate genomic, clinical, and imaging data-all previously collected and pseudonymized-from earlier spontaneous studies carried out by the Hematology Unit. The main goal is to explore how genetic, clinical, and imaging features relate to disease outcomes and to develop predictive models using artificial intelligence (AI) and machine learning (ML). These models may help forecast disease progression and treatment response in the future. By combining different types of data, the research team hopes to develop new methods to predict disease progression and treatment outcomes. No new procedures, tests, or patient visits are required for this study. All the information analyzed will come from existing data collected as part of past clinical practice or previous research projects. Once anonymized, it will no longer be possible to identify individual patients. The anonymized dataset will be securely developed and stored by the bioinformatics team at the Hematology Unit of IRCCS AOUBO.",[27],{"date":202,"type":40},{"date":221,"type":40},"2025-06-30",{"date":223,"type":21},"2028-01-01",{"name":208,"class":47},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":251,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100598722","phase-1-a-study-to-evaluate-a-novel-gene-therapy-in-patients-with-relapsed-and-refractory-multiple-myeloma-100598722","NCT07075185","A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","inMMyCAR","Inclusion Criteria:\n\n* Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease\n* Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody\n* Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1\n* Participants must have acceptable laboratory values as defined by the protocol\n\nExclusion Criteria:\n\n* Participants must not have known central nervous system (CNS) involvement with myeloma\n* Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis\n* Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy\n* Participants cannot require systemic steroids for any condition",{"count":234,"type":21},70,[61],"The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.",[238,27,239,240,241,242,243,244,245,246,247,248,249,250],"Multiple Myeloma in Relapse","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy",[252,29,253,254],"in vivo CAR-T","gene therapy","BMCA","2026-04-22",{"date":257,"type":40},"2026-04-24",{"date":259,"type":40},"2025-07-16",{"date":261,"type":21},"2042-05",{"name":263,"class":137},"Kelonia Therapeutics, Inc.",7,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":89,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":189},"100446279","phase-2-minimal-residual-disease-guided-maintenance-therapy-with-belantamab-mafodotin-and-lenalidomide-after-autologous-hematopoietic-cell-transplantation-in-patients-with-newly-diagnosed-multiple-myeloma-100446279","NCT05091372","Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma","Inclusion Criteria:\n\n* Patients with newly diagnosed multiple myeloma status post 1st auto-HCT (day 60 - 180 post-transplant).\n* Disease status (MRD positive or negative), partial response, or better.\n* Age \\> 18-year and 75-year. Non-English speaking patients are eligible.\n* Karnofsky performance status 70 (Appendix A.).\n* Adequate organ function (Please see Table 2. below). Participant agrees to not donate blood while taking lenalidomide and for 28 days after stopping lenalidomide.\n* Patient agrees to enroll in the lenalidomide REMS program.\n* Woman of child-bearing potential (WOCPB) must abstain from hetersosexual sexual contact or agrees to use a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency (as described in Appendix C), plus one additional effective method at least 28 days before starting therapy (for lenalidomide), during the intervention period, at least 28 days after the last dose of lenalidomide and at least 4 months after the last dose of belantamab mafodotin, and agrees not to donate eggs (ova, oocytes) for reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relation to the first dose of the study intervention.\n\nA WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 10-14 days and also within 24 hours before the first dose of the study intervention.\n\nNonchildbearing potential is defined as follows (by other than medical reasons):\n\n* ≥ 45 years of age and has not had menses for \\>1 year.\n* Patients who have been amenorrhoeic for \\\u003C2 years without a history of a hysterectomy and oophorectomy must have a follicle-stimulating hormone value in the postmenopausal range upon screening evaluation.\n* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. 9. Male participant agrees to contraceptive use that should be consistent with institutional guidelines regarding the methods of contraception for those participating in clinical studies.\n\nMale participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n\n• Refrain from donating sperm during treatment (including dose interruptions) and for 4 weeks after their last dose of lenalidomide.\n\nPLUS, either:\n\n• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.\n\nOR Must agree to use contraception\u002Fbarrier as detailed in Appendix C.\n\n• All prior auto-HCT- related toxicities (defined by National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5 must be ≤ Grade 1 at the time of enrollment except for alopecia, fatigue, and amenorrhea.\n\nExclusion Criteria:\n\n* History of progressive disease at any time before starting maintenance.\n* Patients with smoldering MM (IMWG criteria, Appendix F.).\n* Patients with plasma cell leukemia.\n* Patients with non-secretory MM (no measurable disease on electrophoresis and immunofixation). Patients with a measurable disease on PET scan or bone marrow will be eligible.\n* Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia due to underlying liver disease (serum albumin \\\u003C 3gm\u002FdL), esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria\n* Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil inclusion criteria.\n* Current corneal or epithelial disease (except mild punctate keratopathy; see Appendix E.).\n* Participant must not use contact lenses while participating in this study.\n* Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug.\n* Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.\n* Participant must not have had major surgery ≤ 4 weeks before initiating study treatment.\n* The participant must not have any evidence of active mucosal or internal bleeding.\n* Participant must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.\n* Participant must not have an active infection requiring treatment.\n* Participant must not have evidence of cardiovascular risk, including any of the following:\n\n  1. Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.\n  2. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening.\n  3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.16\n  4. Uncontrolled hypertension (blood pressure that remains above goal despite the concurrent use of three antihypertensive drug classes).\n* Participant must not have known HIV infection.\n* Patients will Hepatitis B will be excluded unless the following criteria can be met (Please, also see Appendix B):\n\nSerology Screening HbcAb+, HbsAg- • HBV DNA undetectable HBsAg+ at screen or within 3 months prior to first dose • HBV DNA undetectable\n\n* Highly effective antiviral treatment started at least 4 weeks prior to first dose of study treatment\n* Baseline imaging per protocol\n* Participants with cirrhosis are excluded\n\nNote: presence of Hep B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.\n\n* Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria (Please, also see Appendix B):\n\n  * RNA test negative\n  * Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a washout period of at least 4 weeks.\n* Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.\n* Participants must not be pregnant or lactating.\n* Patients with cognitive impairments and\u002For any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.",{"count":272,"type":21},94,[62],"To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.",[27],"2026-03-03",{"date":278,"type":40},"2026-03-05",{"date":280,"type":40},"2022-12-01",{"date":282,"type":21},"2027-12-31",{"name":284,"class":47},"M.D. Anderson Cancer Center",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":189},"100627192","feasibility-of-a-multi-omics-platform-for-hematological-malignancies-100627192","NCT07445438","Feasibility of a Multi-omics Platform for Hematological Malignancies","FOCUS","Inclusion Criteria:\n\n* Patient aged \\> 2 year old\n* Retrospective study:\n* Patients previously diagnosed with hematological malignancies\n* Prospective study:\n* Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion).\n* Patients with clinical suspicion of R\u002FR onco-hematological disorder, requiring a diagnostic assessment using BM aspirate\u002Fbiopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc.\n* Patients with blastic transformation from a chronic condition or suspect of R\u002FR hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate\u002Fbiopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc.\n\nExclusion Criteria:\n\n* Age \\\u003C2 year old\n* Patient without a diagnosis of hematological malignancy.","2 Years",{"count":294,"type":21},1040,[24],"This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.",[27,298,299,300,247,301],"Chronic Leukemia","Acute Leukemia","Myeloproliferative Disorders","Myelodysplastic Disorders","2026-02-25",{"date":276,"type":40},{"date":305,"type":40},"2025-03-31",{"date":307,"type":21},"2030-03",{"name":309,"class":47},"Azienda Ospedaliero-Universitaria di Parma",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":105},"100383097","phase-2-a-multicentre-non-blinded-study-exploring-self-administration-of-chemotherapy-in-the-home-environment-100383097","NCT04268199","A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment","EASE","Inclusion Criteria:\n\n* Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,\n* Stable clinical status as deemed by responsible investigator,\n* Personally (or caregiver) willing and deemed capable to self-administer with teaching,\n* Previously received more than 4 injections of bortezomib within the hospital and\u002For cancer centre environment,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Currently participating in clinical trials that includes the use of bortezomib,\n* History of allergic reactions to bortezomib,\n* History of bleeding attributable to bortezomib,\n* History of greater than or equal to grade 3 side effects attributable to bortezomib,\n* Clinically deemed unlikely to be compliant with therapy by responsible investigator,\n* Life expectancy anticipated to be less than 6 months,\n* Deemed geographically inaccessible to receive care.",{"count":318,"type":21},100,[62],"This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.",[119,27],"2025-12-08",{"date":324,"type":40},"2025-12-15",{"date":326,"type":40},"2020-05-29",{"date":328,"type":21},"2026-12",{"name":330,"class":47},"AHS Cancer Control Alberta",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":354,"leadSponsor":356,"locationsCount":105},"100611087","e-motion--promoting-emotion-regulation-in-chronic-cancer-100611087","NCT07236021","e-Motion : Promoting Emotion Regulation in Chronic Cancer","Promoting Emotion Regulation in Patients Living With Chronic Cancer : A Pilot Feasibility, Acceptability and Tolerability Study (e-Motion Project)","Inclusion Criteria:\n\n* Having received a diagnosis of chronic cancer (metastatic breast cancer, metastatic melanoma, metastatic colorectal, metastatic ovarian, metastatic uterine, metastatic endometrial, metastatic prostate, metastatic bladder, metastatic kidney or metastatic testicular cancer, symptomatic multiple myeloma, metastatic non-small cell lung, metastatic mesothelioma or metastatic thymoma) in the past 12 months,\n* Having completed at least one active treatment session (e.g., chemotherapy, surgery, radiotherapy, immunotherapy, target therapy).\n\nExclusion Criteria:\n\n* Having less than one year of life expectancy\n* Having more than one treatment line (for triple negative breast cancer, melanoma, gynecological cancer, colorectal cancer, bladder cancer, kidney cancer, non-small cell lung, mesothelioma and thymoma) or two treatment lines (for other breast cancers and testicular cancer) or three treatment lines (for prostate cancer and multiple myeloma),\n* Having a diagnosis of oligometastatic cancer,\n* Age \\\u003C 18 years,\n* Non-fluency in French,\n* Inability to follow the online intervention,\n* Severe cognitive impairment, and severe and\u002For acute psychiatric disorder.",{"count":80,"type":21},[24],"The present study aimed to pilot evaluate two interventions: a Guided Self-Help Intervention alone, and a combined Group and Guided Self-Help Intervention, designed to support individuals living with chronic cancer and recently diagnosed. The primary aim of this pilot study is to assess the feasibility, acceptability and tolerability of the interventions. The secondary aim of the pilot study is to assess the interventions preliminary efficacy and differences on psychological symptoms.",[342,27],"Metastatic Cancers",[344,345,346,347,348,349],"Advanced cancer","Cognitive Behavioral Therapy (CBT)","Emotional regulation","Ecological Momentary Assessment (EMA)","Hypnosis","Psychotherapy Group","2025-11-20",{"date":352,"type":40},"2025-11-21",{"date":350,"type":40},{"date":355,"type":21},"2026-12-31",{"name":357,"class":47},"Université Libre de Bruxelles",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100510918","phase-2-limited-duration-teclistamab-100510918","NCT05932680","Limited-duration Teclistamab","Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Participants must be age ≥18 and able to give written, informed consent.\n* Participants must have initiated teclistamab (first full dose) 6-9 months prior to enrollment and received an average teclistamab dose of at least 1.5 mg\u002Fkg\u002Fmonth since the date of the first 1.5 mg\u002Fkg dose.\n* Participants must have received a teclistamab dose within 4 weeks prior to enrollment.\n* Participants must have had measurable disease according to IMWG criteria within 1 month prior to teclistamab initiation or first full teclistamab dose\n* Participants must have achieved a confirmed VGPR or better to teclistamab therapy at any assessment prior to enrollment and have ongoing response (i.e., no disease progression) at time of enrollment per IMWG consensus criteria (Appendix 14.3).\n* Prior to initiating teclistamab, participants must have received therapy with a proteasome inhibitor, thalidomide analog (lenalidomide or pomalidomide), and an anti-CD38 antibody and meet one of the following criteria:\n\n  1. ≥3 prior lines of therapy (with lines-of-therapy delineated according to IWMG guidelines)\n  2. Refractory to both a proteasome inhibitor and a thalidomide analog.\n* Participants must have had an ECOG performance status of 0-2 at time of teclistamab initiation; in addition, ECOG performance status must be 0-1 at time of enrollment.\n* Participants must not have known diagnoses of systemic amyloidosis or POEMS syndrome.",{"count":366,"type":21},75,[62],"This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment with teclistamab, a B-cell maturation antigen (BCMA)-directed T-cell engager (anti-BCMAxCD3 bispecific antibody), will be offered monitored drug discontinuation. Teclistamab is typically dosed on a regular schedule (every 1-4 weeks) indefinitely until disease progression (\"continuous therapy\"). Here, a limited-duration regimen will be studied in which patients achieving ≥VGPR after 6-9 months of standard teclistamab dosing will discontinue therapy and resume if laboratory or clinical parameters suggest early disease progression (\"limited-duration therapy\"). Patients will enter the clinical trial protocol after completing 6-9 months of standard teclistamab monotherapy and achieving ≥VGPR. The study's hypothesis is that the failure probability six months after stopping teclistamab in this patient population will be non-inferior compared to that of historical controls treated with continuous therapy. Reducing drug exposure may be beneficial by reducing risk of infection and reducing anti-BCMA selective pressure toward generation of BCMA-negative relapses. Analysis of minimal residual disease (MRD), tumor features, and bone marrow microenvironment parameters, which will be pursued as exploratory correlative analyses in this study, may identify factors that predict durable response to limited-duration therapy and thereby enable more precise selection of patients likely to benefit from this approach. A subset of patients will be enrolled on a biomarker study for analysis of these exploratory endpoints.",[27],"2025-09-29",{"date":372,"type":40},"2025-10-01",{"date":374,"type":40},"2023-07-05",{"date":376,"type":21},"2027-01",{"name":378,"class":47},"Abramson Cancer Center at Penn Medicine",5,{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":388,"targetDuration":390,"studyType":92,"phases":4,"briefSummary":391,"conditions":392,"keywords":407,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":189},"100608743","high-altitude-hematology-observation-stem-cell-transplantation-halo-sct-100608743","NCT07205523","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau","HALO-SCT","Inclusion Criteria:\n\n1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.\n2. Planned or actual hematopoietic stem cell transplantation (HSCT).\n3. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.\n2. Substance abuse compromising adherence.\n3. Any condition judged by investigators to jeopardize safety or compliance.",{"count":389,"type":21},1000,"100 Years","The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.",[393,394,395,396,397,398,399,400,401,402,403,404,118,405,406],"Hematopoietic Stem Cell Transplantation (HSCT)","Acute Myeloid Leukemia (AML)","Leukemias, Acute Myeloid","Myeloid Leukemias, Acute","Hemophilia","Myelodysplastic Syndrome","MDS","Lymphoma","Leukemia","Aplastic Anemia","Bleeding Disorders","Bone Marrow Transplantation","Myeloma, Multiple","Immune Reconstitution",[408],"High-altitude Bone marrow transplantation Allogeneic HSCT Autologous HSCT Immune reconstitution Graft-versus-host disease Relapse Survival Quality of life","2025-09-25",{"date":411,"type":40},"2025-10-03",{"date":413,"type":40},"2023-09-01",{"date":415,"type":21},"2100-12-31",{"name":417,"class":47},"Yigeng Cao,MD,PhD",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":189},"100526337","evaluation-of-the-role-of-connected-scales-in-the-therapeutic-care-of-hematology-patients-100526337","NCT06133426","Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients","BTP","Inclusion Criteria:\n\n* Patient aged 18 and over (male or female)\n* Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma\n* Patient who can be contacted by telephone during their participation in the research\n* Patient able to return home at the end of their initial hospitalization\n* Patient affiliated to social security\n* Patient able to read and speak French\n* Patient having signed free, informed and written consent\n\nExclusion Criteria:\n\n* Patient with an estimated life expectancy \\\u003C 3 months\n* Patient with moderate to severe cognitive impairment (assessed by MMSE \\\u003C 20)\n* Patient with a psychiatric or physical disability that does not allow the use of the device\n* Patient with a pacemaker\n* Patient participating in another intervention research project\n* Pregnant patient\n* Patient deprived of liberty\n* Patient under legal protection (guardianship or curatorship)",{"count":80,"type":21},[24],"In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +\u002F- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform.\n\nAlerts will be generated in the event of abnormal development of certain clinical parameters (weight, heart rate, etc.) allowing early treatment to be implemented by the medical team.\n\nAt the end of their participation, we will evaluate patients' support and perception of this tool, as well as the healthcare consequences of the alerts generated by the remote monitoring platform.",[429,27],"Lymphoma, Non-Hodgkin",[431,432,433],"Hematology","Connected scale","Remote monitoring","2025-09-09",{"date":436,"type":40},"2025-09-15",{"date":438,"type":40},"2025-09-04",{"date":440,"type":21},"2026-05",{"name":442,"class":47},"Assistance Publique - Hôpitaux de Paris",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":189},"100586156","phase-1-the-application-of-car-t-cell-therapy-in-relapsed-and-refractory-malignant-hematologic-tumors-100586156","NCT06911710","The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors","CAR-T","Inclusion Criteria:\n\nWith their own consent and have signed an informed consent form, willing and able to comply with the planned visits, study treatment, laboratory tests and other experimental procedures; Patients with recurrent\u002Frefractory malignant hematologic tumors as determined by clinical diagnosis; Age 18 years and above, both male and female; Subjects with a physical status of 0\\~2 on the Eastern Cooperative Oncology Group (ECOG) score; Expected survival \\>3 months from the date of informed consent; HGB ≥ 60g\u002FL (transfusion is allowed); Liver and kidney function, cardiopulmonary function meet the following requirements: a) creatinine ≤1.5×ULN;b) Left ventricular ejection fraction ≥50%; c) Blood oxygen saturation \\>90%;d) Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; Subjects with pregnancy plans must agree to use contraception prior to enrollment in the study and after the study has lasted for six months; subjects should notify the investigator immediately if they become pregnant or suspect pregnancy.\n\nSubjects in the different cohorts will still be required to fulfill the following conditions:\n\nLymphoma Cohort:\n\nB-cell lymphoma Diagnosis of CD19+ and\u002For CD20+ and\u002For CD22+ and\u002For BAFF+ B-cell lymphoma confirmed by pathology and histology; Inert B-cell lymphoma (CLL, FL, MZL, LPL, HCL); Aggressive B-cell lymphoma (DLBCL, BL, MCL).\n\nMeet the following criteria for relapsed or refractory B-cell lymphoma (meet 1 of the first 2 plus 3 below):\n\nLess than 50% tumor shrinkage or disease progression after 4 courses of standard regimen regulated chemotherapy; relapse after achieving CR after standard regimen chemotherapy; subjects must have received adequate prior therapy, including at least: Anti-CD20 monoclonal antibody; Anthracycline-containing combination chemotherapy. T-cell lymphoma\n\nDiagnosis of CD7+ refractory\u002Frelapsed T-lymphocyte lymphoma confirmed by pathology and histology, meeting any of the following criteria:\n\nRelapsed: Disease relapse determined after having previously received at least two standardized treatment regimens to achieve complete remission, or disease relapse after having undergone stem cell transplantation to achieve complete remission; Refractory: previous treatment with at least two regimens and failure to achieve complete remission after the last treatment, or failure to achieve remission or disease progression after stem cell transplantation.\n\nII Acute lymphoblastic leukemia cohort:\n\nAcute B-lymphoblastic leukemia Refractory\u002Frelapsed B-lymphoblastic leukemia diagnosed as CD19+ and\u002For CD20+ and\u002For CD22+ and\u002For BAFF+ confirmed by immunohistochemistry or flow cytometry.\n\nRefractory\u002Frelapsed B-lymphoblastic leukemia (meeting 1 of the following 4 criteria is sufficient):\n\nRelapse within 6 months of first remission; first refractory without achieving complete remission with 2 cycles of standard chemotherapy regimen; failure to achieve complete remission or relapse after first or multiple lines of salvage chemotherapy; those who are not suitable for HSCT, or who have abandoned HSCT due to medical constraints, or those who have relapsed after HSCT.\n\nAcute T-lymphoblastic leukemia\n\nDiagnosis of CD7+ refractory\u002Frelapsed T-ALL\u002FLBL confirmed by immunohistochemistry or flow cytometry, meeting any of the following criteria:\n\nNo CR after standard chemotherapy; CR after first treatment, but CR lasted less than 12 months; No CR after first or more remedial therapy; Relapse two or more times.\n\nIII. multiple myeloma cohort:\n\nPositive expression of BCMA and\u002For CD19 and\u002For GPRC5D in myeloma cells by flow or immunohistochemistry; Patients with relapsed\u002Frefractory multiple myeloma who have received at least 1 prior therapy (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) or are resistant to proteasome inhibitors and\u002For immunomodulatory agents.\n\nIV. myeloid tumor cohort:\n\nPositive tumor cell antigen test results (CD7 and\u002For CD19 and\u002For CD47) confirmed by immunohistochemistry or flow cytometry; Diagnosis of myeloid tumors, including but not limited to AML and MDS, confirmed by pathology and the patient meets the following\n\nRelapse or refractory requirements:\n\nRelapse: reappearance of leukemic cells in the peripheral blood, or \\>5% of primitive cells found in the bone marrow, or extramedullary relapse after second-line or higher salvage therapy to achieve CR\u002FCRi; Refractory: failure to achieve CR\u002FCRi after at least 2 cycles of standard chemotherapy.\n\nExclusion Criteria:\n\na history of severe cardiac insufficiency with a left ventricular ejection fraction \\\u003C50%; A history of severe lung function-impairing disease; Combination of other malignant tumors in progressive stages; Combination of severe infections that cannot be effectively controlled; Combination of severe autoimmune disease or congenital immunodeficiency; Active hepatitis (Hepatitis B virus deoxyribonucleic acid \\[HBV-DNA\\] or Hepatitis C virus ribonucleic acid \\[HCV-RNA\\] test results above the lower limit of detection); Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection; History of severe allergy to biological products (including antibiotics); Allogeneic hematopoietic stem cell transplantation patients who still have acute graft-versus-host reaction (GvHD) one month after stopping immunosuppressive drugs; Presence of other serious physical or mental illnesses or abnormal laboratory tests that may increase the risk of participation in the study or interfere with the results of the study, as well as patients who, in the opinion of the investigator, are not suitable for participation in this study.",{"count":451,"type":21},90,[61,62],"This study is an open, single-arm, prospective, Phase I\u002FII clinical study using \"3+3\" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed\u002Frefractory malignant hematological neoplasms in subjects.",[455,456,27,457,458,459],"Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)","AML (Acute Myelogenous Leukemia)","B-ALL","T-ALL\u002FLymphoma","T-lymphocyte Lymphoma","2025-04-03",{"date":462,"type":40},"2025-04-04",{"date":464,"type":40},"2024-11-09",{"date":466,"type":21},"2027-02-28",{"name":468,"class":47},"Tianjin Medical University General Hospital",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":479,"conditions":480,"keywords":483,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":505},"100581808","the-norwegian-immunotherapy-in-multiple-myeloma-study-100581808","NCT06855121","The Norwegian Immunotherapy in Multiple Myeloma Study","The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort","NIMMS","Inclusion criteria\n\n* Participants age ≥ 18 years\n* Prior diagnosis of one of the following\n\n  * Multiple myeloma as defined according to IMWG criteria\n  * Primary plasma cell leukemia as defined according to IMWG consensus definition\n  * AL-amyloidosis as defined according to IMWG criteria\n* Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):\n\n  * Teclistamab (Tecvayli)\n  * Elranatamab (Elrexfio)\n  * Talquetamab (Talvey)\n  * Idecabtagene vicleucel (ide-cel\u002FAbecma)\n  * Ciltacabtagene autoleucel (cilta-cel\u002FCarvykti)\n\nExclusion Criteria:\n\n* None",{"count":478,"type":21},400,"The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.",[27,481,482],"Plasma Cell Leukemia","AL Amyloidosis",[484,485,486,487,488,489,490,491,492,493,494,495],"bispesific antibodies","teclistamab","elranatamab","talquetamab","cilta-cel","ide-cel","ciltacabtagene autoleucel","idecabtagene vicleucel","CRS","ICAN","infections","supportive care","2025-02-26",{"date":498,"type":40},"2025-03-03",{"date":500,"type":40},"2025-01-15",{"date":502,"type":21},"2037-12-01",{"name":504,"class":47},"St. Olavs Hospital",23,{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":89,"sex":514,"minAge":57,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":189},"100511848","phase-4-bioequivalence-studies-of-dasatinib-100-mg-100511848","NCT05944783","Bioequivalence Studies of Dasatinib 100 Mg","Bioequivalence Studies of Dasatinib 100 Mg Tablets in Healthy Colombian Subjects in Postprandial Condition","BE-Dasatinib","Inclusion Criteria:\n\n* Men of legal age between 18 to 50 years.\n* Have been clinically diagnosed as healthy by the trial doctor.\n* Subjects with clinical laboratory results within normal ranges and\u002For suitable by medical selection.\n* Non-smoking subjects for the last 3 months.\n* Have signed the informed consent.\n* Body mass index between 18-30 kg\u002Fm2\n* Subject with complete contact information (cell phone and\u002For contact landline, address, email).\n* Subject who has a family member or guardian with a contact telephone number.\n* Subject to the availability of time to comply with scheduled visits and activities.\n\nExclusion Criteria:\n\n* Subject with a diagnosis of renal, cardiac, hepatic, immunological, dermatological, endocrine, gastrointestinal, neurological or psychiatric disease.\n* Subjects diagnosed with positive COVID 19\n* Subject diagnosed with hematological disorders, such as anemia and\u002For polycythemia.\n* Subjects with a history of gastric surgeries.\n* Permanent or temporary use during the last 15 days of any type of medication, both on their own initiative and by medical prescription. Except female patients who are planning regularly with the same contraceptive method in the last 6 months prior to the start of this trial.\n* Smoker in the last 3 months, regardless of the number of cigarettes.\n* Consumption of xanthines from coffee, tea or chocolate during the previous 48 hours\n* Drinker of alcohol in more than 16 grams every week equivalent to 1 beer or 2 glasses of wine during the last 15 days.\n* Consumption of drugs of abuse or psychoactive substances reported as a positive test.\n* Known hypersensitivity to the active substance or to the excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Subject diagnosed with human immunodeficiency virus infection, hepatitis B or positive hepatitis C.\n* Have participated in clinical studies in the 4 months prior to the start of this trial.\n* Have donated blood in the 30 days prior to the start of the trial.","MALE","50 Years",{"count":517,"type":21},46,[519],"PHASE4","A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets \u002F coated tablets, 4 periods. , with a washout time of 7 days between each dose",[27],[523],"Dasatinib , fed condition, bioequivalence","2025-02-10",{"date":526,"type":40},"2025-02-12",{"date":528,"type":21},"2025-09-01",{"date":530,"type":21},"2026-04-30",{"name":532,"class":533},"Centro de Atencion e Investigacion Medica","NETWORK",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":189},"100534961","bortezomib-bendamustine-melphalan-vs-melphalan-for-multiple-myeloma-100534961","NCT06245629","Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study","Inclusion Criteria:\n\n* Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group.\n* Treated with a second ASCT (ASCT2) as part of second line treatment at UUH.\n* Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only.\n\nExclusion Criteria:\n\n* Double (tandem) ASCT in first or second line treatment\n* Allogenic haematopoietic stem cell transplantation as part of first or second line therapy\n* Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2.",{"count":318,"type":21},"This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.",[27],[545,546,547,548],"Autologous hematopoietic stem cell transplantation","Melphalan","Bendamustine","Bortezomib","2024-11-25",{"date":551,"type":40},"2024-11-29",{"date":553,"type":40},"2024-11-24",{"date":555,"type":21},"2025-11-30",{"name":557,"class":47},"Uppsala University",{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":189},"100359926","fluciclovine-petct-in-multiple-myeloma-patients-100359926","NCT03966443","Fluciclovine PET\u002FCT in Multiple Myeloma Patients","PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose","FLUCIPET","Inclusion Criteria:\n\n* Multiple myeloma patients suitable for ASCT treatment\n\nExclusion Criteria:\n\n* Patients with contraindications to ASCT treatment",{"count":567,"type":21},10,"Comparison between image findings at aminoacid PET\u002FCT and FDG PET\u002FCT for myeloma patients",[405,570],"PET-CT","2019-05-28",{"date":573,"type":40},"2019-05-30",{"date":575,"type":40},"2019-03-01",{"date":577,"type":21},"2029-01-31",{"name":579,"class":47},"Oslo University Hospital","Myeloma-Multiple"]